Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid

P. HALL, Pauline de la Μ. Hall, N. MACLACHLAN, Niels A. Thorn, N. THORN, M. W. E. NUDD, M W Nudd, Cassidy Taylor, C. G. TAYLOR, D. B. Garrioch
BJOG: An International Journal of Obstetrics & Gynaecology · 1987 · vol. 94(6) , pp. 554–558 · doi:10.1111/j.1471-0528.1987.tb03150.x · PMID:3304401 · W2101962667
Non-randomised trial OA: closed CC0 ⤵ 35 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Naproxen sodium and mefenamic acid reduced excessive menstrual bleeding by approximately 46-47% in a double-blind crossover study of 35 patients with menorrhagia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Thirty-five patients with menorrhagia were treated in a double-blind crossover study with naproxen sodium and mefenamic acid after measurement of their blood loss during control menstrual cycles. Treatment with these compounds reduced the excessive bleeding by an average of 46 and 47% respectively. Drugs in the prostaglandin synthetase inhibitor group are considered to have an important place in the treatment of menorrhagia.

My notes (saved in your browser only)

MeSH descriptors

Mefenamic Acid Menorrhagia Naproxen Adolescent Adult Clinical Trials as Topic Double-Blind Method Female Humans Mefenamic Acid Mefenamic Acid Menorrhagia Naproxen Naproxen Random Allocation

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (23)

Cited by (31)

Source provenance

crossref
last seen: 2026-05-10T19:04:07.011082+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:28:48.188428+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK